Advertisement
Screener

Onconetix, Inc. (ONCO) Proceeds from (Repayments of) Debt

1.2 / 5 stars · 8/34 Roast Me

Onconetix, Inc. Proceeds from (Repayments of) Debt

Onconetix, Inc. (ONCO) reported Proceeds from (Repayments of) Debt of $33.10 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-12.

Discontinued › Cash Flow › Financing Activities

us-gaap:ProceedsFromRepaymentsOfDebt · last filed 2023-11-17

  • Onconetix, Inc. proceeds from (repayments of) debt for the quarter ending 2023-03-31 was $33.10M.
Period endProceeds from (Repayments of) Debt 3 monthProceeds from (Repayments of) Debt 12 month
2023-03-31$33.10M
10-Q · filed 2023-05-12
2022-12-31$33.10M
10-Q · filed 2023-11-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
HCW Biologics Inc. (HCWB)United States$0.004B-6.15
REVELATION BIOSCIENCES, INC. (REVB)United States$0.004B
Aptevo Therapeutics Inc. (APVO)United States$0.003B
Sunshine Biopharma Inc. (SBFM)$0.003B
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59
Alaunos Therapeutics, Inc. (TCRT)United States$0.003B-1.44
Genprex, Inc. (GNPX)United States$0.003B-0.02
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90